Logo
Login
$ELDN
$2.41 +$0.20 (9.05%) Close

Company Executives

$ELDN Management Team

Dr. David-Alexandre Gros

Chief Executive Officer

Director

Age 52
Compensation $5.645M USD
Sex Male

Mr. Paul Little

Chief Financial Officer

Age 61
Compensation $3.090M USD
Sex Male

Mr. Bryan Smith

Chief Compliance Officer

General Counsel

Corporate Secretary

Age 46
Compensation $1.683M USD
Sex Male

Mr. Keith Katkin

Independent Chairman of the Board

Age 53
Compensation $191.1K USD
Sex Male

Dr. Steven Perrin

President

Chief Scientific Officer

Director

Age 60
Compensation $4.571M USD
Sex Male

Board of Directors

From the proxy statement filed Apr 30, 2026
Directors
8
serving now
Independent
Not stated
the proxy does not say
Average tenure
5.9 years
from year joined
CEO also chairs the board
No
Keith A. Katkin
Director Age On board Independent Committees Other public boards Pay Source
Steven Perrin
Executive officer
 61 2020
6 years
 Not stated None stated None stated Not stated
June Lee
60 2020
6 years
 Not stated
Compensation Committee Nominating and Corporate Governance Committee Science and Technology Committee · Chair
None stated Not stated
Keith A. Katkin
Board chair
 54 2017
9 years
 Not stated
Nominating and Corporate Governance Committee · Chair
Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), Emergent BioSolutions, Inc. (NYSE: EBS) Not stated
Allan D. Kirk
64 2023
3 years
 Not stated
Audit Committee Science and Technology Committee
None stated Not stated
John S. McBride
74 2017
9 years
 Not stated
Audit Committee · Chair Compensation Committee
None stated Not stated
David-Alexandre C. Gros
CEO
 53 2020
6 years
 Not stated None stated None stated Paid as CEO
Jan Hillson
73 2021
5 years
 Not stated
Nominating and Corporate Governance Committee Science and Technology Committee
None stated Not stated
James Robinson
56 2023
3 years
 Not stated
Audit Committee Compensation Committee · Chair
UroGen Pharma (Nasdaq: URGN), Petauri Health Not stated

Each director opens the passage of the proxy that names them. "Not stated" means the proxy does not say; it never means "no". Pay is the proxy's Director Compensation table; the CEO is paid as an executive.

Related-party transactions

3 disclosed in the proxy filed Apr 30, 2026
Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP and MSI BVF SPV, LLC (the BVF Entities)
beneficial owners of more than 5% of our outstanding voting securities
$18,993,948
2024

Acquired shares of Common Stock and 2024 Pre-Funded Warrants in the 2024 Private Placement

Open in proxy
Charles-Edouard Gros
the brother of our Chief Executive Officer
$333,331
2024

Blu-G Nevada Par Equity LLC dba BGN Investing 1, whose shares he beneficially owns, acquired 140,646 shares of Common Stock in the 2024 Private Placement

Open in proxy
Biotechnology Value Fund L.P., Biotechnology Value Fund II, L.P., Biotechnology Value Trading Fund OS LP and MSI BVF SPV, LLC (the BVF Entities)
beneficial owners of more than 5% of our outstanding voting securities
$17,995,069
2024

Acquired 2024 Offering Pre-Funded Warrants in the 2024 Underwritten Offering

Open in proxy

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support
View Pricing Plans